Wellgistics Health Secures $6.5M in New Capital, Refinances All Debt, Enabling Key AI Transaction
Summary
Wellgistics Health has completed a $21 million convertible debt financing, which refinances all outstanding convertible debt and provides $6.5 million in new capital for working capital. The offering was oversubscribed. This capital raise is critical as it satisfies a closing condition for the previously announced "DelivMeds AI Transaction." This financing follows the company's 1-for-50 reverse stock split, which became effective yesterday, and a recent termination of another acquisition attempt. While the capital infusion and debt refinancing are positive for the micro-cap company's immediate viability and strategic plans, the transaction may result in substantial future dilution to existing stockholders, with conversion prices at $6.00 and potentially $50.00 per share, significantly above the current stock price of $3.17. An 8-K filing will provide more details, and shareholder approval for preferred stock creation is required for the automatic exchange provision.
At the time of this announcement, WGRX was trading at $3.17 on NASDAQ in the Technology sector, with a market capitalization of approximately $4.8M. The 52-week trading range was $0.07 to $4.25. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: ACCESS Newswire.